Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder
Copyright © 2021. Published by Elsevier Ltd..
Neuroinflammation has been connected to the pathophysiology of major depressive disorder (MDD) and neurochemical biomarkers of glial pathology could aid the diagnosis and might support patient stratification and monitoring in clinical trials. Our study aimed to determine the utility of glial fibrillary acidic protein (GFAP), a marker of astrocyte activation, for the differential diagnosis and monitoring of MDD. Employing Simoa technology we measured levels of GFAP in prospectively collected serum samples from 81 age-matched patients with MDD, schizophrenia (SZ), bipolar disorder (BP), and healthy controls (HC). Highest GFAP levels were determined for MDD. At a cut-off of 130 pg/ml, MDD could be discriminated with 87% sensitivity from SZ and BP (specificity 70%) and from HC (specificity 56%). GFAP levels increased with age (r = 0.5236, p = 0.0002) and with MDD severity quantified based on the Montgomery-Åsberg Depression Rating Scale (r = 0.4308, p = 0.0221). Neurofilament light chain serum levels were not different in the diagnostic groups and not associated with GFAP levels (r = 0.0911, p = 0.576) pointing to an independence of astrocyte activation on neurodegeneration. Our study provides first evidence that serum GFAP levels could improve the differential diagnosis of MDD and that depression severity could be objectively quantified using serum GFAP levels. Furthermore, serum GFAP might represent a marker to monitor astroglial pathology in the course of MDD.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:144 |
---|---|
Enthalten in: |
Journal of psychiatric research - 144(2021) vom: 27. Dez., Seite 54-58 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Steinacker, Petra [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers |
---|
Anmerkungen: |
Date Completed 25.02.2022 Date Revised 25.02.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.jpsychires.2021.09.012 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM331415933 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM331415933 | ||
003 | DE-627 | ||
005 | 20231225213418.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jpsychires.2021.09.012 |2 doi | |
028 | 5 | 2 | |a pubmed24n1104.xml |
035 | |a (DE-627)NLM331415933 | ||
035 | |a (NLM)34600287 | ||
035 | |a (PII)S0022-3956(21)00551-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Steinacker, Petra |e verfasserin |4 aut | |
245 | 1 | 0 | |a Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.02.2022 | ||
500 | |a Date Revised 25.02.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
520 | |a Neuroinflammation has been connected to the pathophysiology of major depressive disorder (MDD) and neurochemical biomarkers of glial pathology could aid the diagnosis and might support patient stratification and monitoring in clinical trials. Our study aimed to determine the utility of glial fibrillary acidic protein (GFAP), a marker of astrocyte activation, for the differential diagnosis and monitoring of MDD. Employing Simoa technology we measured levels of GFAP in prospectively collected serum samples from 81 age-matched patients with MDD, schizophrenia (SZ), bipolar disorder (BP), and healthy controls (HC). Highest GFAP levels were determined for MDD. At a cut-off of 130 pg/ml, MDD could be discriminated with 87% sensitivity from SZ and BP (specificity 70%) and from HC (specificity 56%). GFAP levels increased with age (r = 0.5236, p = 0.0002) and with MDD severity quantified based on the Montgomery-Åsberg Depression Rating Scale (r = 0.4308, p = 0.0221). Neurofilament light chain serum levels were not different in the diagnostic groups and not associated with GFAP levels (r = 0.0911, p = 0.576) pointing to an independence of astrocyte activation on neurodegeneration. Our study provides first evidence that serum GFAP levels could improve the differential diagnosis of MDD and that depression severity could be objectively quantified using serum GFAP levels. Furthermore, serum GFAP might represent a marker to monitor astroglial pathology in the course of MDD | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Bipolar disorder | |
650 | 4 | |a Blood biomarker | |
650 | 4 | |a GFAP | |
650 | 4 | |a Inflammation | |
650 | 4 | |a Major depressive disorder | |
650 | 4 | |a Schizophrenia | |
650 | 7 | |a Biomarkers |2 NLM | |
650 | 7 | |a Glial Fibrillary Acidic Protein |2 NLM | |
700 | 1 | |a Al Shweiki, Mhd Rami |e verfasserin |4 aut | |
700 | 1 | |a Oeckl, Patrick |e verfasserin |4 aut | |
700 | 1 | |a Graf, Heiko |e verfasserin |4 aut | |
700 | 1 | |a Ludolph, Albert C |e verfasserin |4 aut | |
700 | 1 | |a Schönfeldt-Lecuona, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Otto, Markus |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of psychiatric research |d 1961 |g 144(2021) vom: 27. Dez., Seite 54-58 |w (DE-627)NLM000150541 |x 1879-1379 |7 nnns |
773 | 1 | 8 | |g volume:144 |g year:2021 |g day:27 |g month:12 |g pages:54-58 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jpsychires.2021.09.012 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 144 |j 2021 |b 27 |c 12 |h 54-58 |